MRNA:NASDAQ
Moderna Inc
$47.26
arrow_downward
-1.79%(-0.86) 1D
$47.36
arrow_upward
+0.21% (+0.10)bedtimeAfter hours
Closed: May 21, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MRNA...
Open
$47.63
High
$47.93
Low
$46.48
Mkt. cap
18.75B
Avg. vol.
7.41M
Volume
4.79M
52-wk high
$59.55
52-wk low
$22.29
EPS
-$8.15
Beta
1.05
Shares outstanding
396.79M
No. of employees
5K
News stories
From sources across the web
Yahoo Finance
·
13 hours ago
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
BioSpace
·
1 day ago
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform
Profile
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. Wikipedia
About Moderna Inc
AI content may include mistakes. Learn more